• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Patients with Moderate ADAMTS13 Deficiency have Increased Risk of Dying

September 21, 2017

Thrombotic microangiopathies (TMAs) may develop from diverse group of etiologies. While activity levels less than 10% of ADAMTS13 help to clinically diagnose thrombotic thrombocytopenic purpura (TTP), the significance of mild (41%-70%) or moderate (11%-40%) ADAMTS13 deficiency for patients with TMA is unclear.  Researchers retrospectively examined 254 TMA patient’s charts from three large medical centers in Boston and compared those patients with mild (N=97) or moderate (N=45) ADAMTS13 deficiency to those with normal activity levels (>70%; N=44).  After excluding patients with severe (<10%; N=68) ADAMTS13 deficiency, patients with moderately deficient ADAMTS13 activity tended to be older, more likely to have sepsis (p<0.01), and had a higher international normalized ratio (INR) than patients with no deficiency or mild deficiency (p<0.01).  Furthermore, patients with moderately deficient levels had an increased risk of mortality compared to those with mild deficiency.  Further research is necessary to determine the best treatment for patients with TMA and moderately deficient ADAMTS13 activity levels as well as the underlying etiologies causing TMA.

Reference:

  1. Li A, Bendapudi PK, Uhl L, Hamdan A, Kaufman RM, and RS Makar. Clinical features and outcomes in patients with thrombotic microangiopathy not associated with severe ADAMTS13 deficiency. Transfusion 2017; 57; 2151-2158.

Filed Under

  • CME
  • News
  • Special Transfusion Situations

Recommended

  • Gene Therapy for Hemophilia A Decreases Bleeding

  • Cost-Effectiveness of Transfusions to Prevent Silent Cerebral Infarcts in Children with Sickle Cell Disease

  • Prophylactic Platelet Transfusions are Not Superior to Supportive Care for Dengue Patients with Thrombocytopenia

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley